Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial - O’Brien, M; Paz-Ares, L; Marreaud, S (Lancet Oncol, 2022)